Company Overview - Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases [1][3] - The company has a clinical pipeline targeting two therapeutic areas: Medical Dermatology and Respiratory [3] Medical Dermatology - Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate for treating vitiligo, an autoimmune disorder [3] - The company also has EB01 (1.0% daniluromer cream), which is Phase 3-ready for moderate-to-severe chronic Allergic Contact Dermatitis (ACD) [3] Respiratory - The most advanced respiratory drug candidate is EB05 (paridiprubart), currently evaluated in a U.S. government-funded study for Acute Respiratory Distress Syndrome [3] - EB05 has received two funding awards from the Government of Canada to support its development [3] - Edesa is preparing an investigational new drug application (IND) for EB07 (paridiprubart) to conduct a future Phase 2 study in patients with pulmonary fibrosis [3] Upcoming Events - Edesa will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference on May 5-6, 2025, in Toronto [1][2] - Management is scheduled to present on May 5 at 4:00pm ET [2]
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference